Drug Trial Radar · NCT07754825
A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II clinical study is designed to evaluate the efficacy and safety of LT3001 in the treatment of acute ischemic stroke
Conditions
- Acute Ischemic Stroke
Interventions
LT3001 Drug:high doseDrug
Drug: LT3001 Drug:high dose Administered by intravenous infusion.
LT3001 Drug: low doseDrug
Drug: LT3001 Drug: low dose Administered by intravenous infusion.
PlaceboDrug
Drug: Placebo Administered by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants by mRS(Modified Rankin Scale) score (0 - 1)Time frame: Day 90 after the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.